Menu Close

Korea’s ViroMed acquires DNA-producing facility for clinical trial in U.S.

ViroMed, a Korean developer of biologic drugs, Wednesday announced it has acquired a DNA production facility in San Diego, California, adding a manufacturing function to its value chain to develop its investigational gene therapy VM202 and other candidates.

뉴스 수집 시각 : 2018-07-19T16:36:00.000Z
뉴스 본문 보기 : http://pulsenews.co.kr/view.php?year=2018&no=452611